Advaxis is a startup based in the United States, most recent round Series-c-plus, 1 tracked investor.
Advaxis is a company headquartered in the United States. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Advaxis was an American biotechnology company focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform using Listeria monocytogenes (Lm). The company merged with Ayala Pharmaceuticals in January 2023.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.